HCA
AUTL icon

Harbor Capital Advisors’s Autolus Therapeutics AUTL Stock Holding History

Harbor Capital Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-279,820
Closed -$1.78M – 731
2024
Q1 		$1.78M Sell
279,820
-28,682
-9% -$179K 0.23% 101
2023
Q4 		$1.99M Buy
308,502
+22,437
+8% +$85.6K 0.38% 66
2023
Q3 		$667K Buy
286,065
+41,524
+17% +$118K 0.14% 178
2023
Q2 		$582K Buy
244,541
+22,392
+10% +$53.1K 0.12% 208
2023
Q1 		$409K Buy
222,149
+76,834
+53% +$150K 0.12% 158
2022
Q4 		$276K Sell
145,315
-3,139
-2% -$7.94K 0.27% 74
2022
Q3 		$318K Sell
148,454
-16,452
-10% -$48.7K 0.29% 71
2022
Q2 		$467K Buy
164,906
+1,763
+1% +$5.37K 0.36% 69
2022
Q1 		$680K Sell
163,143
-48,176
-23% -$203K 0.32% 73
2021
Q4 		$1.1M Buy
+211,319
New +$1.27M 0.4% 68

Other funds holding AUTL

SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $39B AUM 18.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Harbor Capital Advisors's AUTL Position: Q2 2024 in Review

Harbor Capital Advisors sold out of Autolus Therapeutics (AUTL) in Q2 2024, closing a stake of 279,820 shares — an estimated $1.78M sold.

Harbor Capital Advisors first reported a position in AUTL in Q4 2021 and held it in 10 quarters. The position peaked at $1.99M in Q4 2023. 111 funds tracked by Wall St. Rank hold AUTL as of Q2 2024.

  • Harbor Capital Advisors reported no remaining Autolus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Harbor Capital Advisors sold 279,820 Autolus Therapeutics shares in Q2 2024, an estimated $1.78M.
  • Harbor Capital Advisors first reported a position in Autolus Therapeutics in Q4 2021 and held it in 10 quarters.
  • Harbor Capital Advisors's Autolus Therapeutics position peaked at $1.99M in Q4 2023.
  • 111 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2024.

Based on Harbor Capital Advisors's 13F filing for Q2 2024, filed 9 Jul 2024.